Moreover, the single application of αCTLA-4 checkpoint inhibitors increased the frequency of antigen-specific IFNγ producing ICOS+ CD4+ T cells correlating with a better therapeutic outcome in human cancer patients [408,409,410,411]. This evidence concerns the gene CD4 and cancer.